ADRB1 and esophageal squamous cell carcinoma: Therefore, for ESCC patients with elevated ADRB1 expression after neoadjuvant treatment, combining ADRB1 inhibitors with existing immune therapies could be a promising strategy to improve long-term treatment outcomes.